The International Trifecta TM and Epic TM Valve‐in‐Valve Registry: Insights Into Clinical & Hemodynamic Outcomes
Catheterization and Cardiovascular Interventions · 2025
DOI: 10.1002/ccd.31492 ↗At a glance
Vergleichsstudie in Catheterization and Cardiovascular Interventions, 2025. Written by Matthias Raschpichler and 9 co-authors. Institution: Leipzig Heart Center, University Clinic of Cardiac Surgery, Leipzig, Germany. Major MEDLINE topics: Heart Valve Prosthesis, Hemodynamics, Aortic Valve, Bioprosthesis. 32 references. The full text is freely available (open access, CC BY 4.0). Funded by: Financial support was provided by the Abbott Structural Heart..
Abstract (original language)
Background
Little is known about the clinical and hemodynamic outcome of valve‐in‐valve transcatheter aortic valve replacement (ViV‐TAVR) for failed Trifecta surgical aortic bioprotheses.
Aims
We aimed to compare outcomes of valve‐in‐valve transcatheter aortic valve replacement (ViV‐TAVR into failed Trifecta TM vs. ViV‐TAVR into a standard aortic bioprosthetic valve with internally mounted leaflets (Epic TM , Abbott, Minneapolis, MN).
Methods
Data of consecutive patients who underwent ViV‐TAVR into either failed Trifecta TM or Epic TM bioprostheses between October 2015 and June 2020 were retrospectively collected within the International Trifecta and Epic Valve‐in‐Valve Registry, and analyzed for a primary composite outcome of 30‐day mortality and/or coronary obstruction (CO), defined as: (1) CO resulting in myocardial infarction and/or cardiogenic shock, or (2) CO requiring emergent coronary intervention.
Results
A total of 76 patients (49 Trifecta, 27 Epic) with a median age of 80 years (interquartile range [IQR] 75.0; 82.0]) and a median Society of Thoracic Surgeons‐score of 5.4 (IQR 4.0; 9.8) were identified. Coronary protection techniques were more frequently performed in Trifecta than Epic patients (29.6% vs. 0%, p = 0.01). The primary composite outcome was observed in three Trifecta versus five Epic cases (6.1% vs. 20%, p = 0.1), which included one case of CO following ViV‐TAVR into Epic requiring stenting. Increased rates of patient‐prosthesis mismatch (PPM) following valve‐in‐Epic were found (41.7% vs. 75%, p = 0.08). Survival at a median of 365 days was 86.2% and did not differ between groups (log‐rank p = 0.37).
Conclusions
Compared to a stented prosthesis without increased risk of CO, ViV‐TAVR into Trifecta prostheses can be performed with low risk of CO and acceptable short‐term clinical outcomes. As the rate of post‐ViV PPM is substantial for both prostheses, careful patient selection is warranted. (NCT05389631).
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Leipzig Heart Center, University Clinic of Cardiac Surgery, Leipzig, Germany.
- Department of Internal Medicine/Cardiology, Leipzig Heart Center, Leipzig, Germany.
- Wessex Cardiothoracic Centre, University Hospital Southampton, Southampton, UK.
- Heart Center Dresden, University Hospital Dresden, Dresden, Germany.
- University Hospital Leuven, Leuven, Belgium.
- Heartcentre Catharina Hospital, Eindhoven, Netherlands.
ORCID profiles: Matthias Raschpichler
Funding
- Financial support was provided by the Abbott Structural Heart.
Cite
APA
Raschpichler, M., Abdel-Wahab, M., Curzen, N., Wilbring, M., Dubois, C., Lam, K., Faerber, G., Nagel, J., Thiele, H., & Borger, M. A. (2025). The International Trifecta TM and Epic TM Valve‐in‐Valve Registry: Insights Into Clinical & Hemodynamic Outcomes. Catheterization and Cardiovascular Interventions. https://doi.org/10.1002/ccd.31492
Vancouver
Raschpichler M, Abdel-Wahab M, Curzen N, Wilbring M, Dubois C, Lam K, et al. The International Trifecta TM and Epic TM Valve‐in‐Valve Registry: Insights Into Clinical & Hemodynamic Outcomes. Catheterization and Cardiovascular Interventions. 2025. doi:10.1002/ccd.31492
BibTeX
@article{Raschpichler2025,
author = {Raschpichler, Matthias and Abdel-Wahab, Mohamed and Curzen, Nick and Wilbring, Manuel and Dubois, Christoph and Lam, Kayan and Faerber, Gloria and Nagel, Jana and Thiele, Holger and Borger, Michael A},
title = {The International Trifecta TM and Epic TM Valve‐in‐Valve Registry: Insights Into Clinical & Hemodynamic Outcomes},
journal = {Catheterization and Cardiovascular Interventions},
year = {2025},
doi = {10.1002/ccd.31492}
}
EUVIMED